Cadrenal Therapeutics, Inc. (CVKD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029632801ex10-1.htm MASTER SERVICES AGREEMENT, DATED AUGUST 21, 2024, BETWEEN THE COMPANY AND LOHMAN & ASSOCIATES, INC Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (this “ Agreement ”) is entered into as of August 21, 2024 (the “ Effective Dat
How this was made
The 30-second read
Why it matters
Based on the provided text, the newest disclosed facts are governance/officer change and the existence of a services agreement; no new operating metrics, trial results, or regulatory decisions are included in the excerpt.
Market read
Traders may monitor for any material strategic shift implied by the officer/director changes, but the excerpt itself does not show a catalyst that should move the stock meaningfully.
What to watch
The excerpt truncates the 8-K; the full Item 5.02 section may include specific names, roles, and compensation details that could change materiality.
Background
The article is an SEC Form 8-K filing for Cadrenal Therapeutics (Item 5.02), including an exhibit for a master services agreement with Lohman & Associates.
Ticker impact
SEC 8-K Item 5.02 for Cadrenal Therapeutics discloses director/officer changes and compensatory arrangements, plus a related services agreement exhibit.
Limited near-term impact; any reaction is likely small and sentiment-driven unless the officer changes are tied to material strategy or financing not shown here.
Form 8-K Item 5.02 is a primary-source corporate action, but the provided excerpt contains mostly boilerplate contract terms and no quantified compensation, guidance, or operational milestone.
Market effects
No clear sector read-through from the excerpt; it is company-specific governance/contract disclosure.
None indicated.
None indicated.
Counterpoint
Director/officer changes can be routine and non-material; the contract exhibit appears to be standard services/retainer language rather than a transformative deal.
Key entities
- public_companyCadrenal Therapeutics, Inc.
Subject of the SEC 8-K; disclosed director/officer changes and compensatory arrangements (Item 5.02).
- service_providerLohman & Associates, Inc.
Counterparty to a master services agreement exhibit for accounting/business strategy/fractional CFO services.
